Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZGN-1061 in Overweight and Obese Subjects With Type 2 Diabetes
NCT03254368Phase 2Completed
- Sponsor
- Zafgen, Inc.
- Start
- Sep 2017
- Primary completion
- Nov 2018
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of aclimostat in type 2 diabetes mellitus (T2DM) and obesity (5 arms), sponsored by Zafgen, Inc. Primary endpoints: Change in HbA1c at 12 weeks, Incidence of adverse events at 12 weeks and 1 more. Started Sep 2017; status: completed.
02
Drugs
aclimostat
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT03254368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03254368.